Collaboration agreement between Almawave and Vivisol to bring Artificial Intelligence to home care. The partnership between the Almaviva Group company specializing in natural language analysis and Big Data services and Vivisol, a Sol Group company, becomes a “first example of this type at national level and aims to develop applied AI solutions to home care, with the broader objective of encouraging de-hospitalization and guaranteeing the patient an adequate and effective therapeutic path within their own home “.
Almawave and Vivisol have already started a collaboration since last April in the RicovAi-19 project, a pilot study with a clinical trial aimed at combating the Covid-19 pandemic, carried out with Ospedali Riuniti di Ancona in the municipality of Offagna. This planning, thanks to the so-called Clinical Stability Indicator (Ai-Csi) developed by Almawave, made it possible to constantly monitor 150 patients at home, providing the treating physicians with an innovative tool to support clinical-therapeutic choices. Now the two companies intend “jointly analyze, study and experiment” products and services useful for improving the effectiveness of home treatments on patients, in particular the chronic or non self-sufficient one, introducing the AI-CSI also in this area of health care “.
Result of a calculation using specific software and technologies, this indicator, explain Almawave and Vivisol, processes the data generated by the detection of over 60 parameters, including for example saturation, temperature, heart and respiratory rate, blood pressure, and returns to the treating physician a value that summarizes the patient’s state of health . Used in conjunction with other clinical solutions, the AI-CSI can facilitate the work of medical and paramedical personnel and, at the same time, improve the effectiveness of treatment and the person’s home care experience.
The progressive lengthening of life expectancy combined with an increase in chronic diseases, pushes Almawave and Vivisol “to invest in solutions that – through Artificial Intelligence – offer unprecedented answers to new needs and guarantee innovation and efficiency in the world of healthcare, also with a view to reducing hospitalizations and the consequent system costs”.
Valeria Sandei, managing director of Almawave, says she is satisfied with “expanding the collaboration relationship with Vivisol and demonstrate that today’s healthcare can receive an extraordinary contribution from Artificial Intelligence. Researching and refining innovative solutions, partly already implemented within the RicovAI-19 project, to be applied to other areas of personal care represents a challenge that we intend to pursue for a long time, making it as protagonists “.” The opportunities and the very mission of the Pnrr – adds Sande – on this front they go in this direction and AI, in line with the wider need for digitization in the country, plays an essential role “.
Claudio Petronio, Central Director of Vivisol Italy, Southern Europe and Brazil, is also on the same wavelength. “We are happy – he affirms – to have renewed the collaboration with Almawave after the promising results of RicovAI-19 in the Marche region and we hope that the new experiments that we will activate in the coming months can make the NHS evolve, guarantee patients more effective treatment paths. and improve their quality of life “. “If the goal of the system is to make the ‘home as the first place of care’, innovation – underlines Petronius- it is one of the founding elements for the homecare sector and we believe that Artificial Intelligence can make an essential contribution to reduce the distance between hospital and territory, favoring an increasingly integrated patient care “.